WINTON GROUP Ltd Grows Position in Stryker Corporation $SYK

WINTON GROUP Ltd lifted its position in shares of Stryker Corporation (NYSE:SYK) by 129.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,200 shares of the medical technology company’s stock after purchasing an additional 17,585 shares during the quarter. WINTON GROUP Ltd’s holdings in Stryker were worth $9,823,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. VanderPol Investments L.L.C. grew its position in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares during the period. KCM Investment Advisors LLC lifted its position in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares during the period. Rossby Financial LCC lifted its position in Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after acquiring an additional 28 shares during the period. Tcfg Wealth Management LLC boosted its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC boosted its stake in Stryker by 0.6% during the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after acquiring an additional 30 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.2%

Shares of Stryker stock opened at $275.99 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a market capitalization of $105.86 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 1.73 and a beta of 0.76. Stryker Corporation has a 52-week low of $270.85 and a 52-week high of $392.95. The company has a 50-day simple moving average of $326.77 and a two-hundred day simple moving average of $327.62.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the company posted $3.13 earnings per share. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. Piper Sandler decreased their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research lowered their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, UBS Group initiated coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. Eighteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $381.40.

Insiders Place Their Bets

In other news, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.